ClinicalTrials.gg

Program

CG-0416

A development code.

Its studies are mostly in Obesity, led by HongKong Curegene Innovation.

Furthest: phase 1, since Jul 9, 20261 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HongKong Curegene Innovation11 open or runningphase 1since Jul 9, 2026Jul 9, 2026Mar 2027phase 1 · NCT07724431

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2026First study: phase 1 study in OverweightFirst studyNCT07724431 · 64 planned · Australia

Ahead

  1. Mar 2027Primary completion: phase 1 study in OverweightNCT07724431

TargetBeta

THRB →read by rule
“CG-0416 is a novel selective, liver-directed thyroid hormone receptor beta (THR-β) agonist, given orally once daily.”study text, by rule · the study

Other programs on THRB

ProgramCompanyFurthest phaseStudies
resmetiromruleMadrigal Pharmaceuticalsphase 422
KYLO-0603Sino Biopharmaceuticalphase 22
KPC000154rulekunming-pharmaceuticals-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07724431Overweight · Australia1Not yet recruitingMar 202764

How it is read

Names in the registry

  • “CG-0416”, 1 entry

Codes read as this program: CG0416.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.